266 related articles for article (PubMed ID: 18413642)
1. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM; Wu CO; Greenberg P; Young N; Barrett J
J Clin Oncol; 2008 May; 26(15):2505-11. PubMed ID: 18413642
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
Haider M; Al Ali N; Padron E; Epling-Burnette P; Lancet J; List A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S44-8. PubMed ID: 27521323
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
4. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; de Witte T; Neukirchen J; Sekeres MA; Brunner AM; Roboz GJ; Steensma DP; Bhatt VR; Platzbecker U; Cluzeau T; Prata PH; Itzykson R; Fenaux P; Fathi AT; Smith A; Germing U; Ritchie EK; Verma V; Nazha A; Maciejewski JP; Podoltsev NA; Prebet T; Santini V; Gore SD; Komrokji RS; Zeidan AM
Blood Adv; 2018 Jul; 2(14):1765-1772. PubMed ID: 30037803
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.
Parikh AR; Olnes MJ; Barrett AJ
Semin Hematol; 2012 Oct; 49(4):304-11. PubMed ID: 23079060
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
7. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
8. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
[TBL] [Abstract][Full Text] [Related]
9. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.
Scheinberg P; Wu CO; Nunez O; Young NS
J Pediatr; 2008 Dec; 153(6):814-9. PubMed ID: 18672253
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes.
Hata T; Tsushima H; Baba M; Imaizumi Y; Taguchi J; Imanishi D; Nagai K; Tomonaga M; Miyazaki Y
Int J Hematol; 2013 Dec; 98(6):687-93. PubMed ID: 24254637
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Sloand EM; Olnes MJ; Shenoy A; Weinstein B; Boss C; Loeliger K; Wu CO; More K; Barrett AJ; Scheinberg P; Young NS
J Clin Oncol; 2010 Dec; 28(35):5166-73. PubMed ID: 21041705
[TBL] [Abstract][Full Text] [Related]
14. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
15. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.
Marsh J; Schrezenmeier H; Marin P; Ilhan O; Ljungman P; McCann S; Socie G; Tichelli A; Passweg J; Hows J; Raghavachar A; Locasciulli A; Bacigalupo A
Blood; 1999 Apr; 93(7):2191-5. PubMed ID: 10090926
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia.
Chang MH; Kim KH; Kim HS; Jun HJ; Kim DH; Jang JH; Kim K; Jung CW
Eur J Haematol; 2010 Feb; 84(2):154-9. PubMed ID: 19912311
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of transfusion-dependent nonsevere aplastic anemia with cyclosporine A plus ATG/ALG versus cyclosporine A plus androgens: a retrospective single center study].
Song L; Peng GX; Wu ZJ; Zhang L; Jing LP; Zhou K; Li Y; Li Y; Ye L; Li JP; Fan HH; Zhao X; Yang WR; Yang Y; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):946-951. PubMed ID: 27995878
[TBL] [Abstract][Full Text] [Related]
19. [Immunosuppressive therapy using antithymocyte globulin and cyclosporin A with or without human granulocyte colony-stimulating factor in children with acquired severe aplastic anemia].
Liu X; Zou Y; Wang S; Zhang L; Yang W; Zhang J; Liu F; Liu T; Chen X; Ruan M; Zhou J; Cai X; Qi B; Chang L; An W; Guo Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):84-9. PubMed ID: 24739716
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome.
Biesma DH; van den Tweel JG; Verdonck LF
Cancer; 1997 Apr; 79(8):1548-51. PubMed ID: 9118037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
